About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
WASHINGTON, D.C. (May 17, 2022) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement on the U.S. District Court for the District of Columbia issued a decision vacating the patient assistance penalty, a provision of a Medicaid rule finalized in 2020, which would have made it harder for biopharmaceutical manufacturers to offer cost-sharing assistance to commercially insured patients:
“Today’s decision to vacate the patient assistance penalty – a provision of a Medicaid rule finalized in 2020 – is a win for patients. Manufacturers provide patient assistance to do just that – assist patients and address gaps in insurance – but instead insurers are siphoning that money away for themselves. We will continue to work with policymakers on solutions that make medicines more affordable and lower what Americans pay out of pocket.”
Press Release
Medicaid
PhRMA Applauds Court’s Decision to Strike Down Patient Assistance Penalty
PhRMA Applauds Court’s Decision to Strike Down Patient Assistance Penalty image